January 27, 2023

We joined a prestigious Cancer Crosslinks 2023 Conference in Oslo

Our team traveled to Oslo and joined the 15th Edition of Cancer Crosslinks organized by the Oslo Cancer Cluster.

The main headline of this year’s Cancer Crosslinks is - New dimensions to the hallmarks of cancer: How is the last decade of discoveries advancing our understanding of cancer biology and transforming precision medicine?

The conference brought together a strong line-up of speakers, researchers, and experts to address and discuss the progress in precision treatment and cancer immunotherapy.

For more info about the program, go to https://lnkd.in/dGgAegFG.

The interaction between researchers and clinicians, which the event promotes, is crucial for our next steps at MultiplexDX.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News